

## Research Article

# Network Pharmacology-Based Study on the Active Ingredients and Mechanism of Pan Ji Sheng Traditional Chinese Medicine Formula in the Treatment of Inflammation

Shiji Wu, Hongliang Jiang , Zongwen Chen, Weining Lu, and Qin Chen 

Gaozhou Hospital of Traditional Chinese Medicine, No. 32 Maoming Avenue, Gaozhou 525200, Guangdong, China

Correspondence should be addressed to Qin Chen; gaozhouchenqin@163.com

Received 27 July 2022; Accepted 20 August 2022; Published 28 September 2022

Academic Editor: Shuli Yang

Copyright © 2022 Shiji Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Pan Ji Sheng Formula is a Chinese medicine formula that enables heat-free detoxification as well as anti-inflammatory and immune-boosting properties. This formula contains eight herbs. Its underlying mechanism is unknown. The bioactive ingredients were screened in our work, and the mechanism of this formula was investigated. **Methods.** Using traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), ingredients in Pan Ji Sheng Chinese medicine formula were screened, and we selected the main bioactive ingredients for web-based research. The targets of bioactive ingredients are primarily obtained from the SwissTargetPrediction and TCMSP databases, and the text mining method is used. STRING and Cytoscape were then used to examine the protein-protein interaction (PPI) networks. To explore the biological function and related pathways, functional annotation and pathway analysis were performed. **Results.** This research discovered 96 bioactive ingredients. Then, 215 potential targets of bioactive ingredients were screened. Through the analysis of the PPI network, we discovered 25 key target genes, which can be described as hub target genes regulated by bioactive ingredients. Bioactive ingredients primarily regulate CASP3, AKT1, JUN, and other proteins. The formula works synergistically to enhance immune response and antiinfection by regulating immune-related pathways, TNF signaling pathways, and apoptosis. **Conclusions.** A variety of bioactive ingredients in the formula could play roles in regulating CASP3, AKT1, and other genes in immune, infection, apoptosis, and tumor-related signaling pathways. Our data point the way forward for future studies on the mechanism of action of this formula.

## 1. Introduction

The climate in China's Lingnan region is standard subtropical. Summers are hot, rainy, as well as wet [1]. Furthermore, Cantonese people prefer to eat fried, dry, and hot foods. It is easy to make people "heat" and "dampness" due to the hot and humid climate, poor diet, and insufficient sleep [2, 3]. The symptoms of "heat" contain fever, thirst, sweating, fatigue, yellow urine, and yellow tongue. The common symptoms of "dampness" contain head pain, chest tightness, sluggishness, and sore or swollen joints. "Heat" and "dampness" are considered to be the cause of many inflammatory disease, cancer, and metabolic disorders [2].

Inflammation is a pathological defense response and it is also the most important protective response [4]. In modern western medicine, clinical experimental data show that the

current conventional treatment for inflammation is anti-inflammatory drugs and antibiotic drugs [5, 6]. Nonsteroidal anti-inflammatory drugs (NSAIDs) are extensively used to reduce inflammation [7]. NSAIDs, such as aspirin and ibuprofen, are effective by inhibiting cyclooxygenase (COX) activity, thereby suppressing inflammatory responses [8]. Although it is effective, some anti-inflammatory drugs can lead to some side effects, such as gastrointestinal damage, gastrointestinal bleeding, and cardiovascular risk [9, 10]. The long-term use of antibiotic drugs can also lead to drug-resistance and seriously affect the treatment effect [11]. Traditional Chinese medicine (TCM) has the advantages of long efficacy and safety, so it is necessary to excavate the TCM compound formulas for treating inflammation.

The ancestors attempted to collect herbs for clearing heat and detoxification, and boiling water for drinking to

eliminate the “heat” in order to get rid of dampness and heat and adapt to the environment. Since this type of herbal medicine was safe to drink, it gradually spread among the people [12, 13]. People gradually dig up various therapeutic properties of traditional Chinese medicine substances under the research of ancient and modern science, and make formulas with heat-clearing and detoxification features with honeysuckle, *Scutellaria baicalensis*, chrysanthemum, isatis root, and other traditional Chinese medicines, so as to enhance immune response and alleviate problems such as getting angry and heavy moisture caused by improper diet and lack of sleep [14, 15]. TCM (traditional Chinese medicine) is a type of traditional medicine. TCM is still a vital resource with such a long history. TCM can still influence the advancement of modern medicine [16, 17]. The Pan Ji Sheng formula, which contains eight different herbs, is the subject of this research: *Microctis Folium* (the leaves of *Microcos paniculata*), *Polygonum chinense* (creeping smartweed), *Ecliptae Herba* (false daisy), *Perilla Frutescens* (the leaves of Beefsteak Plant), *Isatidis Radix* (the dried roots of the plant *Isatis indigotica* Fort or *Isatis tinctoria* L.), *Chrysanthemi Flos* (the flower of *Chrysanthemum indicum* Linne or *Chrysanthemum morifolium* Ramatuelle), *Glycyrrhiza uralensis* (Chinese licorice, the root of *Glycyrrhiza uralensis*), and *Chimonanthus salicifolius* (wintersweet). All of these herbs are commonly used to treat diseases by clinicians. According to published research, these Chinese herbal medicines can prevent and treat diseases by utilizing a wide range of chemical components and multiple targets [18–21]. For example, isatis root lectin can directly kill influenza viruses by blocking the expression of nuclear proteins of new influenza viruses [22]; at the same time, nucleoside components such as uridine, guanosine, and adenosine can interfere with the synthesis of viral nucleic acid and perform critical roles for influenza virus defense [23], and polysaccharides have immunomodulatory effects and play indirect roles for influenza virus defense [24].

There is, however, no systematic research report on the specific formula and network mechanism of the formula’s effects of clearing heat, detoxifying, anti-inflammatory, and enhancing immune response. Now, researchers have realized the “one key, one lock” model is insufficient for deciphering drug effects, particularly in complex diseases [25]. Network pharmacology is a new technology that uses the receptor theory and biological network technology to elucidate drug action mechanisms [26]. Its research mode of “multicomponent network target action” opens up a new research field and its compound prescriptions with multicomponent and multitarget synergy [27]. Furthermore, the rapid development of biomedical data, such as the TCMSP (traditional Chinese medicine system pharmacology database and analysis platform), has facilitated such research [28]. As a result, web-based pharmacological analysis can provide us with a thorough understanding of the significance of each component, target, and pathway. Based on the research concept of traditional Chinese medicine’s multicomponent and multitarget effect, this study explains the biological mechanism of clearing heat, detoxifying, anti-inflammatory, and enhancing immune response by using the

network pharmacology technology and analyzing the target characteristics, biological function, and pathway of the Pan Ji Sheng formula. Our research provides a scientific basis for experimental research and product development.

## 2. Methods

**2.1. Screening of Bioactive Ingredients.** Through TCMSP, we search the relevant information about the bioactive ingredients in eight herbals in Pan Ji Sheng formula and screen the qualified compounds as the formula’s active ingredients. The screening conditions are oral bioavailability (OB)  $\geq 30\%$ , number of hydrogen bond donors (Hdon)  $< 5$ , lipid water partition coefficient (Alogp)  $< 5$ , number of hydrogen bond receptors (HACC)  $< 10$ , intestinal epithelial permeability (Caco-2)  $> 0$ , drug class (DL)  $\geq 0.18$ , and drug half-life (HL)  $\geq 4$ . We obtained bioactive ingredients of six herbals (*Microctis Folium*, *Ecliptae Herba*, *Perilla Frutescens*, *Isatidis Radix*, *Chrysanthemi Flos*, and *Glycyrrhiza uralensis*) from the TCMSP database. There is no information about *Polygonum chinense* and *Chimonanthus salicifolia* in the TCMSP database, so we search the literature for bioactive ingredients of these two herbals, then test OB  $\geq 30\%$  and DL  $\geq 0.18$  in TCMSP to determine the active ingredients.

**2.2. Target Prediction of Bioactive Ingredients.** The formula’s bioactive ingredients were imported to TCMSP to obtain information on ingredient-target interaction. Second, we use the Swiss Target Prediction online analysis tool to predict the active ingredient’s targets, screen potential targets, extract the names of the target genes, and build the chemical ingredient-target interaction network. The specific method is to convert all ingredients into standard smiles format and import the smiles format file into the Swiss Target Prediction online analysis platform [29], set the species to “*Homo sapiens*,” and set Probability  $\geq 0.7$ , and export the target data in the CSV format.

The target genes were then imported to the UniProt database to confirm their gene names. Through computer research, this study obtained the list of target genes for the traditional Chinese medicine Pan Ji Sheng formula.

**2.3. Construction of the Protein-Protein Interaction (PPI) Network.** We import target genes into STRING [30] and set the species to “*Homo sapiens* (human)” and use a confidence level of 0.9 to build the target interaction network (PPI). We hide the discrete points in the network, then export the results to a TSV file and import it to Cytoscape 3.9.1 [31]. Cytoscape was then used to construct the target’s PPI network.

Then, in Cytoscape, the MCODE and Cytohubba plugins were used to extract the functional modules and top 25 hub genes of the PPI network, respectively.

**2.4. Gene Ontology (GO) Functional Annotation and KEGG Pathway Analysis.** All screened target genes were entered into the Metascape platform for enrichment analysis [32].

TABLE 1: Herbal and bioactive ingredients of Pan Ji Sheng formula.

Herbals	Molecule names
<i>Microctis folium</i>	Isorhamnetin
	Kaempferol
	4',5-Dihydroxyflavone
	Kaempferol Quercetin
<i>Polygonum chinense</i>	3-O-Methylellagic acid
	Kaempferol-7-O-glucoside
	3,3'-Di-O-methylellagic acid
	Protocatechuic acid
	Isorhamnetin Luteolin Acacetin
<i>Ecliptae herba</i>	Butin
	1,3,8,9-Tetrahydroxybenzofurano [3,2-c] chromen-6-one
	3'-O-Methylorobol
	Pratensein
	Demethylwedelolactone Wedelolactone Luteolin
<i>Perilla frutescens</i>	Luteolin
	Acacetin
	Eupatorin
	Dinatin
	Quindoline
	Hydroxyindirubin
	Indigo (2Z)-2-(2-Oxoindolin-3-ylidene) indolin-3-one
<i>Isatidis radix</i>	2-(9-((3-Methyl-2-oxopent-3-en-1-yl) oxy)-2-oxo-1,2,8,9-tetrahydrofuro [2,3-h] quinolin-8-yl) propan-2-yl acetate
	DFV
	(E)-2-[(3-Indole) cyanomethylene-]-3-indolinone
	neohesperidin_qt
	Sinensetin
	6-(3-Oxoindolin-2-ylidene) indolo[2,1-b]quinazolin-12-one
	(E)-3-(3,5-Dimethoxy-4-hydroxy-benzylidene)-2-indolinone
	(E)-3-(3,5-Dimethoxy-4-hydroxyb-enzylidene)-2-indolinone
	3-[(3,5-Dimethoxy-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-2,4-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-one
	[(1S,5S,7S)-7-Acetoxy-5-isopropenyl-2,8-dimethylene-cyclodecyl] acetate
Acacetin Chryseriol Isorhamnetin	
<i>Chrysanthemi flos</i>	Kaempferol
	5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl) chroman-4-one
	Luteolin
	Eupatorin
	Diosmetin
	Naringenin
	Artemetin
	Jaranol Isorhamnetin Formononetin

TABLE 1: Continued.

Herbals	Molecule names
	Calycosin
	Kaempferol
	Licochalcone a
	Inermine
	DFV
	Glycyrol
	Medicarpin
	Lupiwighteone
	7-Methoxy-2-methyl isoflavone
	Naringenin
	Glyasperin B
	Glyasperin F
	Isotrifoliol
	(E)-1-(2,4-Dihydroxyphenyl)-3-(2,2-dimethylchromen-6-yl) prop-2-en-1-one
	(2S)-6-(2,4-Dihydroxyphenyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro [3,2-g] chromen-7-one
	Semilicoisoflavone B
	Glepidotin A
	Glepidotin B
	Glypallichalcone
	8-(6-Hydroxy-2-benzofuranyl)-2,2-dimethyl-5-chromenol
	Licochalcone B
	Licochalcone G
	Licoricone
	Gancaonin A
	Gancaonin B
	3-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-8-(3-methylbut-2-enyl) chromone
	5,7-Dihydroxy-3-(4-methoxyphenyl)-8-(3-methylbut-2-enyl) chromone
	2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-(3-methylbut-2-enyl) chromone
<i>Licorice</i>	Licocoumarone
	Licoisoflavone
	Licoisoflavone B
	Licoisoflavanone
	Shinpterocarpin
	(E)-3-[3,4-Dihydroxy-5-(3-methylbut-2-enyl)phenyl]-1-(2,4-dihydroxyphenyl) prop-2-en-1-one
	Glyzaglabrin
	Glabranin
	Glabrone
	1,3-Dihydroxy-9-methoxy-6-benzofurano[3,2-c] chromenone
	1,3-Dihydroxy-8,9-dimethoxy-6-benzofurano[3,2-c] chromenone
	Eurycarpin A
	Sigmoidin-B
	(2R)-7-Hydroxy-2-(4-hydroxyphenyl) chroman-4-one
	(2S)-7-Hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl) chroman-4-one
	Isoglycyrol
	Isolicoflavonol
	HMO
	1-Methoxyphaseollidin
	Quercetin der.
	6-Prenylated eriodictyol
	7-Acetoxy-2-methylisoflavone
	8-Prenylated eriodictyol
	Gancaonin G
	Gancaonin H
	Licoagrocarpin
	Glyasperins M
	Licoagroisoflavone
	Odoratin
	Phaseol
	Xambioona
<i>Chimonanthus salicifolius</i>	Luteolin-5-O-glucoside
	Quercetin
	Kaempferol

TABLE 2: Potential target genes of bioactive ingredients of Pan Ji Sheng formula.

No.	Target gene names	String Id
1	NOS2	9606.ENSPO0000327251
2	PTGS1	9606.ENSPO0000354612
3	ESR1	9606.ENSPO0000405330
4	AR	9606.ENSPO0000363822
5	PPARG	9606.ENSPO0000287820
6	PTGS2	9606.ENSPO0000356438
7	PTPN1	9606.ENSPO0000360683
8	ESR2	9606.ENSPO0000343925
9	DPP4	9606.ENSPO0000353731
10	MAPK14	9606.ENSPO0000229795
11	GSK3B	9606.ENSPO0000324806
12	HSP90AA1	9606.ENSPO0000335153
13	CDK2	9606.ENSPO0000266970
14	PIK3CG	9606.ENSPO0000352121
15	PKIA	9606.ENSPO0000379696
16	PRSS1	9606.ENSPO0000308720
17	PIM1	9606.ENSPO0000362608
18	CCNA2	9606.ENSPO0000274026
19	NCOA2	9606.ENSPO0000399968
20	CALM2	9606.ENSPO0000272298
21	PYGM	9606.ENSPO0000164139
22	PPARD	9606.ENSPO0000310928
23	CHEK1	9606.ENSPO0000388648
24	AKR1B1	9606.ENSPO0000285930
25	NCOA1	9606.ENSPO0000385216
26	F7	9606.ENSPO0000364731
27	F2	9606.ENSPO0000308541
28	NOS3	9606.ENSPO0000297494
29	ACHE	9606.ENSPO0000303211
30	GABRA1	9606.ENSPO0000393097
31	MAOB	9606.ENSPO0000367309
32	GRIA2	9606.ENSPO0000296526
33	RELA	9606.ENSPO0000384273
34	XDH	9606.ENSPO0000368727
35	NCF1	9606.ENSPO0000289473
36	OLR1	9606.ENSPO0000309124
37	PGR	9606.ENSPO0000325120
38	CHRM1	9606.ENSPO0000306490
39	GABRA2	9606.ENSPO0000421828
40	SLC6A2	9606.ENSPO0000219833
41	CHRM2	9606.ENSPO0000399745
42	ADRA1B	9606.ENSPO0000306662
43	TOP2A	9606.ENSPO0000411532
44	IKBKB	9606.ENSPO0000430684
45	AKT1	9606.ENSPO0000451828
46	BCL2	9606.ENSPO0000381185
47	BAX	9606.ENSPO0000293288
48	CD40LG	9606.ENSPO0000359663
49	JUN	9606.ENSPO0000360266
50	AHSA1	9606.ENSPO0000216479
51	CASP3	9606.ENSPO0000311032
52	MAPK8	9606.ENSPO0000378974
53	MMP1	9606.ENSPO0000322788
54	STAT1	9606.ENSPO0000354394
55	CDK1	9606.ENSPO0000378699
56	HMOX1	9606.ENSPO0000216117
57	CYP3A4	9606.ENSPO0000337915
58	CYP1A1	9606.ENSPO0000369050
59	ICAM1	9606.ENSPO0000264832

TABLE 2: Continued.

No.	Target gene names	String Id
60	SELE	9606.ENSPO0000331736
61	VCAM1	9606.ENSPO0000294728
62	NR1I2	9606.ENSPO0000336528
63	CYP1B1	9606.ENSPO0000478561
64	ALOX5	9606.ENSPO0000363512
65	HAS2	9606.ENSPO0000306991
66	AHR	9606.ENSPO0000242057
67	PSMD3	9606.ENSPO0000264639
68	SLC2A4	9606.ENSPO0000320935
69	NR1I3	9606.ENSPO0000356959
70	INSR	9606.ENSPO0000303830
71	DIO1	9606.ENSPO0000354643
72	GSTM1	9606.ENSPO0000311469
73	GSTM2	9606.ENSPO0000241337
74	AKR1C3	9606.ENSPO0000369927
75	SLPI	9606.ENSPO0000342082
76	NOX4	9606.ENSPO0000263317
77	AVPR2	9606.ENSPO0000351805
78	MAOA	9606.ENSPO0000340684
79	IGF1R	9606.ENSPO0000268035
80	FLT3	9606.ENSPO0000241453
81	CYP19A1	9606.ENSPO0000379683
82	EGFR	9606.ENSPO0000275493
83	CA2	9606.ENSPO0000285379
84	AURKB	9606.ENSPO0000313950
85	DRD4	9606.ENSPO0000176183
86	ADORA1	9606.ENSPO0000356205
87	CA7	9606.ENSPO0000345659
88	GLO1	9606.ENSPO0000362463
89	MPO	9606.ENSPO0000225275
90	PIK3R1	9606.ENSPO0000428056
91	ADORA2A	9606.ENSPO0000336630
92	DAPK1	9606.ENSPO0000386135
93	PYGL	9606.ENSPO0000216392
94	CA1	9606.ENSPO0000430656
95	SRC	9606.ENSPO0000362680
96	PTK2	9606.ENSPO0000341189
97	HSD17B2	9606.ENSPO0000199936
98	KDR	9606.ENSPO0000263923
99	MMP13	9606.ENSPO0000260302
100	CA12	9606.ENSPO0000178638
101	CA13	9606.ENSPO0000318912
102	CA9	9606.ENSPO0000367608
103	GPR35	9606.ENSPO0000411788
104	ERBB2	9606.ENSPO0000269571
105	CCND1	9606.ENSPO0000227507
106	CDK4	9606.ENSPO0000257904
107	PDGFRB	9606.ENSPO0000261799
108	FLT4	9606.ENSPO0000261937
109	CCNA1	9606.ENSPO0000255465
110	PLK1	9606.ENSPO0000300093
111	CA6	9606.ENSPO0000366654
112	CA14	9606.ENSPO0000358107
113	CSNK2A1	9606.ENSPO0000217244
114	MET	9606.ENSPO0000317272
115	CA4	9606.ENSPO0000300900
116	PLK4	9606.ENSPO0000270861
117	TEK	9606.ENSPO0000369375
118	TNF	9606.ENSPO0000398698
119	IL2	9606.ENSPO0000226730

TABLE 2: Continued.

No.	Target gene names	String Id
120	RPS6KA3	9606.ENSPO0000368884
121	CD38	9606.ENSPO0000226279
122	PDE5A	9606.ENSPO0000347046
123	NQO2	9606.ENSPO0000369822
124	ADRA2C	9606.ENSPO0000386069
125	ALDH2	9606.ENSPO0000261733
126	NMUR2	9606.ENSPO0000255262
127	ADRA2A	9606.ENSPO0000280155
128	SLC29A1	9606.ENSPO0000377424
129	AURKA	9606.ENSPO0000216911
130	CA5A	9606.ENSPO0000309649
131	BACE1	9606.ENSPO0000318585
132	MAP3K8	9606.ENSPO0000263056
133	BRAF	9606.ENSPO0000288602
134	BCL2L1	9606.ENSPO0000302564
135	CDKN1A	9606.ENSPO0000384849
136	CASP9	9606.ENSPO0000330237
137	MMP2	9606.ENSPO0000219070
138	MMP9	9606.ENSPO0000361405
139	MAPK1	9606.ENSPO0000215832
140	IL10	9606.ENSPO0000412237
141	RB1	9606.ENSPO0000267163
142	CDK4	9606.ENSPO0000257904
143	IL6	9606.ENSPO0000385675
144	TP53	9606.ENSPO0000269305
145	NFKBIA	9606.ENSPO0000216797
146	TOP1	9606.ENSPO0000354522
147	MDM2	9606.ENSPO0000258149
148	APP	9606.ENSPO0000284981
149	PCNA	9606.ENSPO0000368458
150	CASP7	9606.ENSPO0000358327
151	MCL1	9606.ENSPO0000358022
152	BIRC5	9606.ENSPO0000301633
153	CCNB1	9606.ENSPO0000256442
154	TYR	9606.ENSPO0000263321
155	IFNG	9606.ENSPO0000229135
156	IL4	9606.ENSPO0000231449
157	XIAP	9606.ENSPO0000360242
158	PTGES	9606.ENSPO0000342385
159	NUF2	9606.ENSPO0000271452
160	ADCY2	9606.ENSPO0000342952
161	ADRB2	9606.ENSPO0000305372
162	PDE3A	9606.ENSPO0000351957
163	CASP8	9606.ENSPO0000351273
164	FASN	9606.ENSPO0000304592
165	FASLG	9606.ENSPO0000356694
166	RXRA	9606.ENSPO0000419692
167	LACTBL1	9606.ENSPO0000402297
168	SCN5A	9606.ENSPO0000410257
169	F10	9606.ENSPO0000364709
170	RHO	9606.ENSPO0000296271
171	KCNH2	9606.ENSPO0000262186
172	KCNMA1	9606.ENSPO0000286628
173	SLC6A4	9606.ENSPO0000261707
174	CHRNA7	9606.ENSPO0000407546
175	PPP3CA	9606.ENSPO0000378323
176	MAPK3	9606.ENSPO0000263025
177	LDLR	9606.ENSPO0000454071
178	BAD	9606.ENSPO0000378040
179	SOD1	9606.ENSPO0000270142
180	MTTP	9606.ENSPO0000427679

TABLE 2: Continued.

No.	Target gene names	String Id
181	APOB	9606.ENSPO0000233242
182	PLB1	9606.ENSPO0000330442
183	HMGCR	9606.ENSPO0000287936
184	UGT1A8	9606.ENSPO0000304845
185	PPARA	9606.ENSPO0000385523
186	SREBF1	9606.ENSPO0000348069
187	GSR	9606.ENSPO0000221130
188	ABCC1	9606.ENSPO0000382342
189	ADIPOQ	9606.ENSPO0000389814
190	SOAT2	9606.ENSPO0000301466
191	AKRIC1	9606.ENSPO0000370254
192	GOT1	9606.ENSPO0000359539
193	ABAT	9606.ENSPO0000379845
194	CES1	9606.ENSPO0000353720
195	SOAT1	9606.ENSPO0000356591
196	ADRA1D	9606.ENSPO0000368766
197	SLC6A3	9606.ENSPO0000270349
198	SIRT1	9606.ENSPO0000212015
199	ATP5B	9606.ENSPO0000262030
200	MT-ND6	9606.ENSPO0000354665
201	HSD3B2	9606.ENSPO0000445122
202	HSD3B1	9606.ENSPO0000358421
203	STAT3	9606.ENSPO0000264657
204	EIF6	9606.ENSPO0000363574
205	FOSL2	9606.ENSPO0000264716
206	CHRM3	9606.ENSPO0000255380
207	OPRM1	9606.ENSPO0000394624
208	DRD1	9606.ENSPO0000377353
209	CHRM5	9606.ENSPO0000372750
210	CHRM4	9606.ENSPO0000409378
211	HTR2A	9606.ENSPO0000437737
212	MAPK10	9606.ENSPO0000352157
213	OPRD1	9606.ENSPO0000234961
214	ADRB1	9606.ENSPO0000358301
215	LTA4H	9606.ENSPO0000228740

The hub targets were imported into the David database to clarify their function and role in signal transduction. GO biological process enrichment analysis and KEGG signal pathway analysis are carried out. The enrichment analysis results are enhanced with the R program package and displayed in the form of a bubble diagram.

*2.5. Construction of the Bioactive Ingredients-Hub Target Network.* Cytoscape 3.9.1 software was used to build the bioactive ingredients-hub target network. In this network, nodes represent bioactive ingredients and hub targets.

*2.5.1. Hub Target-GO BP/Pathway/Disease Network.* Use Cytoscape 3.9.1 to build the network model. Nodes represent hub targets, pathways, and diseases, and edges represent interactions between these nodes.

### 3. Results

*3.1. Screening of Bioactive Ingredients of the Pan Ji Sheng Formula.* The bioactive ingredients of eight Chinese herbal




FIGURE 1: Enrichment analysis for bioactive ingredient targets by Metascape website. (a, b) Top 20 clusters with their representative enriched terms. (c) :Enrichment heatmap of the selected GO parents.

medicines from the Pan Ji Sheng formula were screened from the TCMSP platform in this study. Because there is no relevant information on the TCMSP platform for *Polygonum chinense* and *Chimonanthus salicifolia*, we obtained the active components of these two herbals through literature retrieval and then tested whether they meet the standards of oral bioavailability (OB)  $\geq$  30 percent and drug class (DL)  $\geq$  0.18 in TCMSP. We obtained the active components of the other six herbals from TCMSP. In total, this study screened 96 active ingredients from eight herbals in the Pan Ji Sheng formula (Table 1).

**3.2. Screening of Target Genes.** Target genes of bioactive components were obtained using the TCMSP platform and Swiss target prediction screening. After removing the repeated target genes, we obtained a total of 214 target genes in this study (Table 2). For details of target genes, see Table S1.

**3.3. Enrichment Analysis of All Target Genes.** Using the Metascape website, this study firstly discovered relevant significantly enriched GO/KEGG terms for all target genes. Figure 1 depicts the findings of the analysis. Many target genes are enriched in cancer and lipid metabolism-related pathways (Figures 1(a) and 1(b)). A subset of enriched terms was chosen and rendered as a network plot to further capture the relationships between the terms (Figure 1(c)).

We also analyzed related diseases and expression patterns of all target genes through Metascape, as shown in Figure 2. Diabetes, reperfusion injury, and fatty liver disease are the three most common diseases associated with target

genes. The tissues that expressed the target genes were the lung and liver. According to preliminary findings, the target gene may be linked to lung and liver diseases.

**3.3.1. PPI Network for All Targets.** We upload the names of all target genes to STRING. According to network statistics, the number of nodes is 214, the number of edges is 3057, and the average node degree is 28.6. The expected number of edges is 1173, and the local clustering coefficient is 0.583. We discovered that the network had far more interactions than expected. This suggests that the target proteins as a group are at least partially biologically connected.

Using Cytoscape 3.9.1, we constructed a PPI network (Figure 3(a)). Then, using the Cytoscape plug-in “cytohubba,” we analyzed hub targets and chose the top 25 target genes as hub genes (Figure 3(b)). CASP3, AKT1, Jun, STAT3, TP53, MMP9, BCL211, SRC, and other proteins. The higher the rank, the more important these target genes are in disease treatment. Hub targets are painted red and located at the center of the network for further analysis and research.

We also used the Cytoscape plug-in “MCODE” to examine the PPI network clusters and modules of all target genes (Figure 4). The PPI network is divided into six clusters, with 25 hub target genes located in Cluster 1, indicating that hub genes have biological function relevance and may play a synergistic role.

**3.4. Herbal-Key Bioactive Ingredient-Hub Target Network.** After obtaining the hub target genes, we analyzed the active ingredients corresponding to these 25 hub genes, which are




FIGURE 2: Related diseases and expression patterns of all target genes. (a) The summary of enrichment analysis in Disgenet. (b) The summary of enrichment analysis in PaGenBase.

named as key bioactive ingredients. For more information, see Table S2. The network of herbal-key bioactive ingredient-hub targets was constructed using Cytoscape 3.9.1 (Figure 5). In addition to *Perilla frutescens*, the other seven Chinese herbal medicines have three or more corresponding key bioactive ingredients. Some hub genes are affected by multiple bioactive ingredients at the same time. The primary targets of the active ingredients are MAPK14, HSP90AA1, PTGS2, and ESR1. These genes may be the primary targets of the formula.

**3.5. GO Functional Annotation and KEGG Pathway Analysis.** To investigate the biological processes engaged in hub targets, GO enrichment analysis and KEGG enrichment analysis on 25 hub genes were analyzed in the David website. The mechanism of action of the formula can be researched, based on the biological process regulated by the hub target.

Beautify the enrichment analysis results with *R* (Figure 6). In total, 226 GO biological process enrichment results were obtained. Negative regulation of the apoptotic process,

positive regulation of the nitric oxide biosynthetic process, and positive regulation of transcription from the RNA polymerase II promoter are the top three enrichment biological processes. As shown in Figure 6(a), the top 20 GO biological processes are represented in the form of a bubble diagram, where the size of the circle represents the enrichment of relevant targets in the pathway, and the darker the color of the circle represents the degree of enrichment of targets, indicating that the formula could have physiological effects by regulating these biological processes.

For KEGG pathway enrichment analysis, 25 hub targets were mapped into the David database. The species was defined as “human,” and a total of 94 pathways were obtained. As shown in Figure 6(d), the top 20 pathways with high significance of KEGG enrichment results are closely related to the mechanism of the Pan Ji Sheng formula. The top five pathways include hepatitis B, pathways in cancer, TNF signaling pathway, toxoplasmosis, and toll-like receptor signaling pathway. The majority of these pathways are linked to the genes TP53, JUN, AKT1, MAPK14, HSP90AA1, and PTGS2.






FIGURE 3: PPI network of all target genes. (a) PPI network, colored and in the middle are 25 hub genes. (b) Top 25 genes in the network ranked by the MCC method in "CytosHubba".




FIGURE 4: Clusters 1-6 in the PPI network. Among them, 25 hub genes are painted red and orange.




FIGURE 5: Herbal-key bioactive ingredient-hub target network.




FIGURE 6: GO and KEGG enrichment analysis of hub genes.




FIGURE 7: Disease and disease class enrichment analysis of hub genes.




FIGURE 8: Hub target-GO BP/pathway network.

We also performed disease enrichment analysis to investigate diseases associated with hub targets. Figure 7 shows the classification of diseases enriched in hub targets. The three major categories are cancer, infection, and immune system. Our findings indicate that the formula studied in this study may primarily target these diseases.

**3.5.1. Hub Target-GO BP/Pathway/Disease Class Network.** In order to demonstrate the biological process of the hub target and the relationship between the hub target and the pathway more clearly, the hub target-GO BP/pathway/disease class network was built with Cytoscape 3.9.1 software (Figure 8).

The hub target is represented by the circle in the center of Figure 8. The left and right sides of Figure 8 show the top 20 enriched biological processes and pathways, respectively. We can clearly understand the relationship between the targets and biological processes or pathways. MAPK14, hsp90AA1, and PTGS2 genes are associated with apoptotic biological processes, TNF signaling pathways, toll-like receptor signaling pathways, and cancer pathways. The formula could play a significant role by regulating these pathways.

In order to demonstrate the link between the hub targets and diseases more clearly, Cytoscape 3.9.1 software was used to create a network of hub targets and diseases (Figure 9). The genes MAPK14, HSP90AA1, PTGS2, and ESR1 have been linked to cancer, infection, and immune disease.




FIGURE 9: Hub target-disease class network.

#### 4. Discussion

Traditional Chinese medicine formulas are typically difficult to decipher due to the action mode of traditional Chinese medicine formulas [33]. Using network pharmacology, this study explains the action mechanism of the Pan Ji Sheng Chinese medicine formula. According to the findings of this study, CASP3, AKT1, JUN, and other genes are the hub targets of the formula to enhance immune response and anti-inflammatory.

According to the active ingredient-target network, HSP90AA1, PTGS2, ESR1, and MAPK14 are the four key genes regulated by the active ingredient of the Pan Ji Sheng formula. HSP90AA1 is an inflammation-related protein that can be significantly upregulated with some inflammation-related genes in the inflammatory response [34, 35]; PTGS2 is involved in inflammation, immunity, and other processes [36, 37]; ESR1 is also involved in inflammation and immunity and is one of the key targets for the treatment of pneumonia [38, 39]; and MAPK14 is related to autophagy and plays an important role in immune response [40].

As shown in the results, 19 of the 25 hub targets were discovered to be involved in the pathways in cancer, with the pathways in cancer being the most significant pathway. This could be due to the fact that respiratory inflammation and lung disease are risk factors for cancer [41, 42]. Other top KEGG enrichment pathways include hepatitis B, the TNF signaling pathway, toxoplasmosis, and the toll-like receptor signaling pathway. A key target gene is tumor necrosis factor

(TNF), a cytokine secreted by macrophages and adipocytes. It can cause IR by suppressing the activity of the PI3K/Akt signaling pathway. TNF has been shown to activate MAPK and NF- $\kappa$ B signaling pathways, which regulate inflammatory response, oxidative stress, and apoptosis [43, 44].

The network pharmacological analysis reveals that the Pan Ji Sheng formula could regulate HSP90AA1, PTGS2, ESR1, MAPK14, and other genes, modulating pathways such as cancer pathways, TNF signaling pathways, and toll-like receptor signaling pathways to regulate inflammatory response and immune processes.

This study investigated the anti-inflammatory and immune mechanisms of Pan Ji Sheng formula. However, *in vivo* and *in vitro* experiments are needed to provide more information on the mechanism of action of the formula.

#### 5. Conclusions

The active components of the Pan Ji Sheng formula could regulate certain proteins, including HSP90AA1, PTGS2, ESR1, and MAPK14. The Chinese herbs in the Pan Ji Sheng formula have a synergistic therapeutic effect, primarily by acting on inflammation and immune-related signal pathways. Pan Ji Sheng formula plays the functions through multicomponents, multitargets (HSP90AA1, PTGS2, ESR1, MAPK14, and other hub targets), and multipathways (inflammation and immune-related signal pathways). These findings could serve as guidelines for future research into this formula. Based on the present study, functional

experiments can be performed on animal models or human cells to validate the pharmacological mechanisms of the Pan Ji Sheng formula in the future. This research has theoretical significance for the TCM pharmacology and has application value for the development and utilization of TCMs.

### Data Availability

The data used to support the findings of this study are included within the supplementary information files.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Authors' Contributions

Qin Chen and Shiji Wu designed the experiments; Shiji Wu, Hongliang Jiang, and Zongwen Chen collected and assembled the data; data analysis was done by Shiji Wu, Hongliang Jiang, and Weining Lu; the manuscript was written by all the authors; final approval of the manuscript was done by all the authors.

### Supplementary Materials

Table S1: targets of Pan Ji Sheng Formula. Table S2: detailed information of herbal-key bioactive ingredients-top 25 hub targets. (*Supplementary Materials*)

### References

- [1] Z. Zeng, L. Li, and Y. Pang, "Analysis on climate adaptability of traditional villages in Lingnan, China-World cultural heritage site of majianglong villages as example," *Procedia Engineering*, vol. 205, pp. 2011–2018, 2017.
- [2] H. Rong-Rong, Y. Xin-Sheng, and K. Hiroshi, "The "Xiehuo" effect of Guangdong herbal tea and its composition," *World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica*, vol. 11, pp. 834–839, 2009.
- [3] M. H. Pan, S. R. Zhu, W. J. Duan et al., "Shanghuo increases disease susceptibility: modern significance of an old TCM theory," *Journal of Ethnopharmacology*, vol. 250, Article ID 112491, 2020.
- [4] L. Chen, H. Deng, H. Cui et al., "Inflammatory responses and inflammation-associated diseases in organs," *Oncotarget*, vol. 9, no. 6, pp. 7204–7218, 2018.
- [5] L. Dall, S. Peterson, T. Simmons, and A. Dall, "Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy," *Cutis*, vol. 75, no. 3, pp. 177–180, 2005.
- [6] J. F. Chmiel, M. W. Konstan, and J. S. Elborn, "Antibiotic and anti-inflammatory therapies for cystic fibrosis," *Cold Spring Harbor Perspectives in Medicine*, vol. 3, no. 10, Article ID a009779, 2013.
- [7] G. A. Green, "Understanding NSAIDs: from aspirin to COX-2," *Clinical Cornerstone*, vol. 3, no. 5, pp. 50–59, 2001.
- [8] R. E. Harris, J. Beebe-Donk, H. Doss, and D. Burr Doss, "Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review)," *Oncology Reports*, vol. 13, no. 4, pp. 559–583, 2005.
- [9] L. Laine, "Gastrointestinal effects of NSAIDs and coxibs," *Journal of Pain and Symptom Management*, vol. 25, no. 2, pp. 32–40, 2003.
- [10] F. Marsico, S. Paolillo, and P. P. Filardi, "NSAIDs and cardiovascular risk," *Journal of Cardiovascular Medicine*, vol. 18, pp. e40–e43, 2017.
- [11] A. Nande and A. L. Hill, "The risk of drug resistance during long-acting antimicrobial therapy," *medRxiv*, 2021.
- [12] H. Rongrong, Y. Xinsheng, and K. Hiroshi, "Studies on the "Xiehuo" effect and compositions of Guangdong herbal tea," *World Science and Technology*, vol. 11, no. 6, pp. 834–839, 2009.
- [13] S. Li, S. K. Li, D. P. Xu, A. N. Li, and H. B. Li, "Herbal Teas," in *Handbook of Functional Beverages and Human Health (1st ed.)*, F. Shahidi and C. Alasalvar, Eds., CRC Press, Boca Raton, FL, USA, 2016.
- [14] R. R. He, B. Tsoi, Y. F. Li, X. S. Yao, and H. Kurihara, "The anti-stress effects of Guangdong herbal tea on immunocompromise in mice loaded with restraint stress," *Journal of Health Science*, vol. 57, no. 3, pp. 255–263, 2011.
- [15] Y. H. Luo, Y. Q. Huang, and H. Yang, "Research progress of Chinese herbal medical liangcha," *Strait Pharmaceutical Journal*, vol. 5, 2006.
- [16] J. Xu and Y. Zhang, "Traditional Chinese medicine treatment of COVID-19," *Complementary Therapies in Clinical Practice*, vol. 39, Article ID 101165, 2020.
- [17] Y. Xiang, Z. Guo, P. Zhu, J. Chen, and Y. Huang, "Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science," *Cancer Medicine*, vol. 8, no. 5, pp. 1958–1975, 2019.
- [18] J. Yu, J. Guo, W. Tao et al., "Gancao-Gansui combination impacts gut microbiota diversity and related metabolic functions," *Journal of Ethnopharmacology*, vol. 214, pp. 71–82, 2018.
- [19] M. Yang, J. Luo, Q. Yang, and L. Xu, "Research on the medication rules of Chinese herbal formulas on treatment of threatened abortion," *Complementary Therapies in Clinical Practice*, vol. 43, Article ID 101371, 2021.
- [20] H. Yuan, S. Jiang, Y. Liu et al., "The flower head of *Chrysanthemum morifolium* Ramat. (Juhua): a paradigm of flowers serving as Chinese dietary herbal medicine," *Journal of Ethnopharmacology*, vol. 261, Article ID 113043, 2020.
- [21] L. Cheng, F. Wang, S. B. Zhang, and Q. Y. You, "Network pharmacology integrated molecular docking reveals the anti-COVID-19 and SARS mechanism of Fufang Banlangen Keli," *Natural Product Communications*, vol. 16, 2021.
- [22] A. Prasad, M. Muthamilarasan, and M. Prasad, "Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules," *Plant Cell Reports*, vol. 39, no. 9, pp. 1109–1114, 2020.
- [23] Y. Mizukami, "Character of frontier orbitals of antiviral drugs: candidate drugs against COVID-19," *Open Journal of Physical Chemistry*, vol. 10, no. 03, pp. 158–165, 2020.
- [24] C. T. Lee, K. S. Huang, J. F. Shaw et al., "Trends in the immunomodulatory effects of cordyceps militaris: total extracts, polysaccharides and cordycepin," *Frontiers in Pharmacology*, vol. 11, Article ID 575704, 2020.
- [25] K. C. Chou, "Distorted key theory and its implication for drug development," *Current Proteomics*, vol. 17, no. 4, pp. 311–323, 2020.
- [26] Z. Zhou, B. Chen, S. Chen et al., "Applications of network pharmacology in traditional Chinese medicine research," *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 1646905, 7 pages, 2020.

- [27] J. Muhammad, A. Khan, A. Ali et al., "Network pharmacology: exploring the resources and methodologies," *Current Topics in Medicinal Chemistry*, vol. 18, no. 12, pp. 949–964, 2018.
- [28] J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines," *Journal of Cheminformatics*, vol. 6, pp. 13–16, 2014.
- [29] D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, and V. Zoete, "SwissTargetPrediction: a web server for target prediction of bioactive small molecules," *Nucleic Acids Research*, vol. 42, no. W1, pp. W32–W38, 2014.
- [30] D. Szklarczyk, A. L. Gable, K. C. Nastou et al., "The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets," *Nucleic Acids Research*, vol. 49, no. D1, pp. D605–D612, 2021.
- [31] D. Otasek, J. H. Morris, J. Bouças, A. R. Pico, and B. Demchak, "Cytoscape automation: empowering workflow-based network analysis," *Genome Biology*, vol. 20, pp. 185–215, 2019.
- [32] Y. Zhou, B. Zhou, L. Pache et al., "Metascape provides a biologist-oriented resource for the analysis of systems-level datasets," *Nature Communications*, vol. 10, pp. 1523–1610, 2019.
- [33] R. Guo, X. Luo, J. Liu, L. Liu, X. Wang, and H. Lu, "Omics strategies decipher therapeutic discoveries of traditional Chinese medicine against different diseases at multiple layers molecular-level," *Pharmacological Research*, vol. 152, Article ID 104627, 2020.
- [34] A. D. Zuehlke, K. Beebe, L. Neckers, and T. Prince, "Regulation and function of the human HSP90AA1 gene," *Gene*, vol. 570, no. 1, pp. 8–16, 2015.
- [35] X. Xiao, W. Wang, Y. Li et al., "HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma," *Journal of Experimental & Clinical Cancer Research*, vol. 37, pp. 201–213, 2018.
- [36] T. Kosaka, A. Miyata, H. Ihara et al., "Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2," *European Journal of Biochemistry*, vol. 221, no. 3, pp. 889–897, 1994.
- [37] J. Li, X. Kong, J. Zhang, Q. Luo, X. Li, and L. Fang, "MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer," *Cancer Cell International*, vol. 13, pp. 7–6, 2013.
- [38] D. R. Robinson, Y. M. Wu, P. Vats et al., "Activating ESR1 mutations in hormone-resistant metastatic breast cancer," *Nature Genetics*, vol. 45, no. 12, pp. 1446–1451, 2013.
- [39] F. Holst, P. R. Stahl, C. Ruiz et al., "Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer," *Nature Genetics*, vol. 39, no. 5, pp. 655–660, 2007.
- [40] Y. Hirota, S. I. Yamashita, Y. Kurihara et al., "Mitophagy is primarily due to alternative autophagy and requires the MAPK1 and MAPK14 signaling pathways," *Autophagy*, vol. 11, no. 2, pp. 332–343, 2015.
- [41] G. Lee, T. C. Walser, and S. M. Dubinett, "Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer," *Current Opinion in Pulmonary Medicine*, vol. 15, no. 4, pp. 303–307, 2009.
- [42] A. H. Wu, E. T. H. Fontham, P. Reynolds et al., "Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States," *American Journal of Epidemiology*, vol. 141, no. 11, pp. 1023–1032, 1995.
- [43] G. Chen and D. V. Goeddel, "TNF-R1 signaling: a beautiful pathway," *Science*, vol. 296, no. 5573, pp. 1634–1635, 2002.
- [44] J. R. Bradley, "TNF-mediated inflammatory disease," *The Journal of Pathology*, vol. 214, no. 2, pp. 149–160, 2008.